Abstract | INTRODUCTION: METHODS: A comprehensive literature review identified relevant studies, from which data were meta-analyzed over 3-month intervals up to 24 months. Patient-centered outcomes of interest included mean (95% CI) changes from baseline (Δ) in quality of life (QoL), measured using PD-specific (PDQ-8, PDQ-39) and generic (EQ-5D) instruments; activities of daily living ( ADL), measured in On and Off states using UPDRS Part II; and motor symptoms (i.e., Off time/day and motor examination [measured in On and Off states using UPDRS Part III]). RESULTS: The pooled meta-analysis included data from 26 studies evaluating 1556 patients on CLES. At 3 months, all outcomes showed significant improvement: QoL (ΔPDQ-39 = -10.26 [-11.54, -8.97], ΔEQ-5DVAS = 15.42 [12.58, 18.26]); ADL (ΔUPDRS IION = -4.32 [-5.63, -3.01]); motor symptoms (ΔOff time hours/day = -3.48 [-4.15, -2.82], ΔUPDRS IIION = -6.20 [-9.88, -2.51]). At 24 months, there were statistically significant mean improvements in QoL (ΔPDQ-39 = -7.74 [-12.40, -3.07], ΔEQ-5DVAS = 11.18 [6.90, 15.45]) and ADL (ΔUPDRS IIOFF = -3.88 [-5.34, -2.42]), and Off time (-4.21 [-5.16, -3.26] hours/day). CONCLUSIONS: Impact of CLES on significantly reducing Off time/day was observed to be rapid and durable (i.e., remained consistent across 24 months). Most QoL and ADL measures showed a consistent pattern of improvement with initiation of treatment and remained significantly improved from baseline at 24 months.
|
Authors | David G Standaert, Vardhaman Patel, Sonya J Snedecor, Sandeep Thakkar, Yash J Jalundhwala, Pavnit Kukreja, David Kratochvil, Yanjun Bao, Rajesh Pahwa |
Journal | Parkinsonism & related disorders
(Parkinsonism Relat Disord)
Vol. 86
Pg. 52-57
(05 2021)
ISSN: 1873-5126 [Electronic] England |
PMID | 33857722
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- Antiparkinson Agents
- Drug Combinations
- Gels
- carbidopa, levodopa drug combination
- Levodopa
- Carbidopa
|
Topics |
- Activities of Daily Living
- Antiparkinson Agents
(administration & dosage)
- Carbidopa
(administration & dosage)
- Drug Combinations
- Gels
- Humans
- Infusion Pumps, Implantable
- Levodopa
(administration & dosage)
- Parkinson Disease
(drug therapy)
- Quality of Life
|